NOT YET RECRUITING
NCT06872801
Home High-Flow Nasal Cannula vs. Noninvasive Ventilation for Stable Chronic Respiratory Failure
The goal of this clinical trial is to compare the effects of home high-flow nasal cannula (HFNC) therapy and noninvasive ventilation (NIV) in patients with stable chronic hypercapnic respiratory failure. The main questions it aims to answer are:
* Does HFNC or NIV reduce blood carbon dioxide levels more effectively?
* How well do patients tolerate and adhere to each therapy?
* Are there differences in oxygen saturation, respiratory rate, and quality of life between the two treatments?
Participants Will:
* Use either HFNC (myAirvo2®) or NIV (Trilogy Evo®) every night for at least 4 hours over a 6-week period.
* Visit the hospital for checkups and arterial blood gas tests at the end of each 6-week period.
* Switch to the alternate device after six weeks as part of the crossover study design.
* Have their device usage recorded and analyzed.
Gender: All
Ages: 40 Years - Any
Stable Chronic Hypercapnic Respiratory Failure